Advanced Proteome Announces Agreement With The University of Iowa for Testing of Foundation Trinity(TM) Technology

VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 29, 2013) - Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE:APC) is pleased to announce that it has executed an agreement with The University of Iowa on behalf of Dr. Joel Shilyansky for the testing of protein conjugates and multimers as part of APC's "Foundation Trinity™" technology. Dr. Shilyansky holds the Robert and Hélène Soper Chair of Pediatric Surgery at the University of Iowa Carver College of Medicine. Dr. Shilyansky will be performing the testing of APC's protein modifications in the University of Iowa laboratories to determine their effects on tumor growth and immunogenicity. A focal point of his interest is the protection from tumor challenge, afforded by proteins with high affinity for cancers cells, through immune-mediated mechanisms.

Dr. Krantz, President and CEO of APC, stated "As part of our program of preclinical testing of APC's proprietary protein modifications, we are excited about the prospect of having Dr. Shilyansky and his colleagues evaluate the effects of APC's protein conjugates and multimers in their highly sophisticated experimental models and assays."

About APC

APC specializes in the development and patenting of advanced methods and platform technologies designed to deliver drugs to specific cellular targets. The Company's patent-pending technology creates transportation systems for drugs to target cells that need to be destroyed, such as cancer cells. APC uses its proprietary enabling technology for chemical modification of the carrier proteins. These methods allow the drug, in accord with regulatory requirements, to be site-specifically attached to the carrier protein which tracks to cancers cells. APC is focused on developing the first commercial application of cancer cell targeting by a specific protein family that has an affinity for cancer cells. Due to its high affinity for a target receptor on cancer cells, the protein can function as a transport system for drugs linked to its surface, with the prospect of avoiding the debilitating toxic effects that have plagued the use of chemotherapeutic drugs. By virtue of a similar affinity of the protein family for cells in the process of dying, the foregoing technologies are also applicable to the repair of cells where loss of function is a critical event, such as in eye diseases and myocardial infarction.

ON BEHALF OF THE BOARD

Alexander (Allen) Krantz, President and Chief Executive Officer

The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations. Forward looking statements include operating risks such as (i) market acceptance of the Company's technology and products, (ii) the Company's ability to obtain and enforce timely patent protection of its technology and products, (iii) the Company's ability to manufacture its products cost effectively and produce favorable research results; (iv) the competitive environment and impact of technological change, and (v) the continued availability of capital to finance the Company's activities. A listing of potential risks can be found in the Company's SEDAR filings.